HealthEquity (NASDAQ:HQY - Get Free Report) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 3.610-3.78 for the period, compared to the consensus earnings per share estimate of 3.620. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the company. Royal Bank of Canada boosted their target price on HealthEquity from $112.00 to $117.00 and gave the stock an "outperform" rating in a research report on Wednesday. Bank of America boosted their target price on HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday. Barrington Research reiterated an "outperform" rating and set a $112.00 price target on shares of HealthEquity in a report on Friday, April 11th. JMP Securities lifted their price target on HealthEquity from $110.00 to $117.00 and gave the company a "market outperform" rating in a report on Wednesday. Finally, The Goldman Sachs Group lifted their price target on HealthEquity from $94.00 to $104.00 and gave the company a "neutral" rating in a report on Wednesday. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $115.82.
Get Our Latest Report on HealthEquity
HealthEquity Stock Up 2.0%
NASDAQ HQY traded up $2.31 on Thursday, reaching $115.37. The stock had a trading volume of 689,981 shares, compared to its average volume of 819,436. HealthEquity has a 1 year low of $65.01 and a 1 year high of $116.69. The business has a 50 day moving average price of $90.51 and a 200 day moving average price of $97.67. The company has a market capitalization of $9.98 billion, a price-to-earnings ratio of 105.84, a P/E/G ratio of 1.60 and a beta of 0.45. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51.
HealthEquity (NASDAQ:HQY - Get Free Report) last announced its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million during the quarter, compared to analysts' expectations of $322.25 million. HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same quarter in the previous year, the firm earned $0.80 earnings per share. On average, analysts forecast that HealthEquity will post 2.32 EPS for the current fiscal year.
Insider Buying and Selling
In other news, Director Robert W. Selander sold 5,750 shares of the business's stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the sale, the director now directly owns 84,969 shares in the company, valued at $6,597,842.85. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Henry Fiore sold 8,881 shares of HealthEquity stock in a transaction dated Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the completion of the sale, the executive vice president now directly owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55% decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is owned by corporate insiders.
HealthEquity Company Profile
(
Get Free Report)
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
See Also

Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.